Drug Database
TL

TLX007-CDx (TLX007 CDx / TLX007CDx)

✓ Approved

Telix Pharmaceuticals Limited · 影像药物 · 影像药物

什么是 TLX007-CDx?

TLX007-CDx 是一种影像药物,由Telix Pharmaceuticals Limited研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名TLX007 CDx, TLX007CDx
公司Telix Pharmaceuticals Limited
药物类别影像药物
给药途径Unknown
状态Approved

治疗适应症

TLX007-CDx 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancerBLA/NDA

相关研究文献

PubMedOral and maxillofacial surgery2026-11-19

Rare parotid gland metastasis from colorectal cancer: a case report and review of the literature.

Wang Yue Y, Hong Lei L, Chen Kaipai K, Lam Alfred King-Yin AK et al.

Metastasis of colorectal carcinoma (CRC) to the parotid gland is exceptionally rare, with only a few cases reported in the literature. We describe a 70 year old woman previously treated for sigmoid adenocarcinoma who developed a painful right parotid mass three years after hemicolectomy and adjuvant XELOX chemotherapy. Fine needle aspiration confirmed metastatic sigmoid colon adenocarcinoma through characteristic immunohistochemical markers, including CDX 2 and Villin positivity. A review of the 8 reported cases (including the current one) shows the disease occurs in patients at a mean age of 63 years (range, 34 to 83). There is no gender or side predilection. The overall features indicate that parotid metastasis from CRC typically occurs with widespread disease and carries a poor prognosis. Diagnosis is challenging because parotid metastases often mimic primary salivary gland tumours clinically and radiologically, making immunohistochemistry essential for distinguishing intestinal adenocarcinoma from primary salivary malignancies. Reported outcomes remain poor, reflecting advanced systemic disease at presentation. This case emphasises the need to consider metastatic CRC in the differential diagnosis of new parotid masses in patients with a history of colorectal malignancy. Early recognition, accurate diagnosis through imaging and histopathology, and multidisciplinary management are crucial. This case highlights the importance of considering metastatic CRC in the differential diagnosis of parotid masses in patients with a known primary malignancy.

PMID 43052594
阅读全文 →
PubMedGan to kagaku ryoho. Cancer & chemotherapy2026-11-16

[Development and Clinical Implementation of Companion Diagnostics in Personalized Medicine-Perspectives on Regulatory Approval, Reimbursement, and Japan-US Differences in Regulatory Systems].

Saito Tatsuro T

Companion diagnostics (CDx) are in vitro diagnostics (IVD) or medical devices (MD) used to identify patients who are expected to benefit from, or avoid safety risks associated with, a specific therapeutic product based on biomarker results. In precision oncology, the clinical value of molecularly targeted therapy depends on accurate patient selection using appropriately validated assays. This review summarizes the regulatory and reimbursement landscape for CDx and related genetic testing in Japan, with selected comparisons to the United States. The article outlines the definition of CDx, the distinction between primary and follow-on CDx, cross-drug CDx, and major product configurations, including IVD products, MD programs, and combination MD systems. Key development considerations include coordination with drug development, use of clinical trial assays, bridging to the final CDx, sample availability, and strategies for rare biomarkers. The review also discusses US features such as FDA oversight of companion diagnostics, group labeling, laboratory developed tests, and payer coverage pathways. Finally, it examines Japanese reimbursement categories for CDx, multi-gene tests, comprehensive genomic profiling, and the gap between test costs and reimbursement when CGP includes CDx functions. These differences indicate that successful CDx development requires not only analytical and clinical validation, but also early planning for labeling, laboratory workflow, payer coverage, reimbursement level, and sustainable access in routine oncology practice.

PMID 43039369
阅读全文 →
PubMedGan to kagaku ryoho. Cancer & chemotherapy2026-11-16

[Clinical Challenges of Genetic Testing in Routine Practice and Proposals for Solutions-The Evolving Role of Companion Diagnostics].

Kishikawa Satsuki S, Yatabe Yasushi Y

Companion diagnostics (CDx) and other molecular tests have been essential components of precision oncology, guiding treatment selection according to individual tumor profiles. In the 2000s, CDx largely followed a"one drug-one biomarker" model, in which single analyte assays for makers such as HER2, EGFR, and KRAS were paired with specific targeted therapies. With the rapid expansion of molecularly targeted agents and immune checkpoint inhibitors, this model has become increasingly limited. As a result, next-generation sequencing (NGS)-based multiplex CDx assays have been adopted to access multiple actionable alterations simultaneously. More recently, tumor-agnostic agents targeting NTRK fusions or MSI-H/ dMMR have further accelerated a shift toward organ- and drug-agnostic diagnostic platforms. In lung cancer, several multi-plex CDx and multi-gene tests-including the Lung Cancer Compact Panel, Oncomine Dx Target Test, AmoyDx, and MINtS are now widely used. Each has distinct advantages and limitations in terms of required sample volume, gene coverage, turnaround time, and cost. Therefore, test selection and its combination can be arranged according to clinical context and institutional resources. At the same time, practical challenges remain, including false-negative results due to suboptimal specimens or incomplete gene coverage, as well as delays in reporting and limitations in reimbursement. This article reviews the evolving role of companion diagnostics, the challenges and potential strategies for appropriately integrating these genetic tests into routine clinical practice, and future perspectives in this field.

PMID 43039370
阅读全文 →
PubMedGan to kagaku ryoho. Cancer & chemotherapy2026-11-16

[Cancer Gene Panel Testing-Current Status and Challenges in Japan].

Sunami Kuniko K

Comprehensive genomic profiling (CGP) using next-generation sequencing enables simultaneous analysis of multiple cancer-related genes and facilitates personalized treatment by identifying potentially actionable genomic alterations. In Japan, CGP has been covered by the national health insurance system since 2019 and has become increasingly integrated into routine cancer care. However, the proportion of patients who ultimately receive genomically matched therapy remains limited, and translating genomic findings into actual treatment remains a major challenge. In Japan, gene panel testing serves 2 roles: companion diagnostics (CDx), which determine eligibility for specific approved therapies, and CGP, which comprehensively analyzes genomic alterations to explore potential therapeutic options. Although these functions can coexist within the same gene panel test, CDx and CGP are managed under different reimbursement frameworks. In addition, restrictions on the institutions and timing of CGP testing, as well as requirements for expert panel review, may hinder timely translation of genomic findings into treatment. In 2025, 3 major Japanese cancer societies issued a briefing report proposing an ideal framework for cancer genomic medicine, including integrated use of CDx and CGP, earlier implementation of CGP, and more efficient use of expert panels. Subsequently, the 2026 reimbursement revision allowed expert panel review to be omitted in selected cases, and an Advanced Medical Care program was initiated to evaluate CGP before completion of standard therapy. Further efforts should focus on performing CGP in appropriate patients at appropriate times, ensuring timely and accurate interpretation and reporting of results, and improving access to genomically matched therapies to more effectively translate genomic information into patient treatment.

PMID 43039371
阅读全文 →
PubMedDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2026-11-16

AKR1B1-dependent ferroptosis defense contributes to KRASG12C inhibitor resistance in pancreatic ductal adenocarcinoma.

Guan Xiaoqing X, Yang Wenyan W, Yao Zhiyang Z, Cao Fei F et al.

To investigate the role of AKR1B1-associated ferroptosis defense in acquired KRASG12Cinhibitor (G12Ci) resistance in pancreatic ductal adenocarcinoma (PDAC) cells, and to evaluate the antitumor activity of AKR1B1 inhibition combined with KRASG12C inhibition in xenograft models. Sotorasib- and adagrasib-resistant PDAC cell populations were analyzed using integrated genomic, transcriptomic, proteomic, and phosphoproteomic profiling. The functional roles of AKR1B1 and YAP1 were assessed using siRNA-mediated knockdown, ferroptosis-rescue assays, and pharmacological inhibition with epalrestat. The combination of epalrestat and sotorasib was also evaluated in treatment-naïve cell line-derived and patient-derived xenograft models. Multi-omics profiling identified AKR1B1 upregulation in sotorasib- and adagrasib-resistant MIA PaCa-2 cells. In these in vitro resistant cell models, AKR1B1 knockdown reduced YAP1 and SLC7A11 expression and cystine uptake, while increasing lipid peroxidation. Epalrestat enhanced the growth-inhibitory effects of G12Ci in resistant cells, with localized synergy at selected concentrations. In treatment-naive MIA PaCa-2 CDX, KRASG12C-mutant PDX, and UMUC3 CDX models, epalrestat plus sotorasib suppressed tumor growth more than either agent alone. AKR1B1-associated ferroptosis defense contributes to acquired KRAS G12Ci resistance in PDAC cell models, and AKR1B1 inhibition enhances sotorasib activity in treatment-naive xenograft models. These findings support further evaluation of AKR1B1 inhibition as a combination strategy for KRASG12Cmutant PDAC.

PMID 43038728
阅读全文 →
PubMedCell death & disease2026-11-16

SRSF2 mutations contribute to bone marrow immune microenvironment alterations.

Tao Changrui C, Li Wei W, Jiang Yu Y, Fan Shu S et al.

Somatic SRSF2 mutations are early lesions in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), yet how they contribute disease remain unclear. In this study, we generated two murine models that have not yet developed overt MDS/CMML-like phenotypes: (i) a cell-derived xenograft (CDX) by tail-vein injection of stable BA/F3-KRASG12C-SRSF2P95H cells and (ii) a Vav1-Cre conditional knock-in mouse heterozygous for Srsf2P95H. Molecular assays, bulk RNA-seq, and single-cell RNA-seq (scRNA-seq) were used to profile the bone-marrow (BM) microenvironment. CDX mice carrying SRSF2P95H displayed systemic immune dysregulation. Bulk RNA-seq of Vav1-Cre BM revealed attenuated T cell chemotaxis and elevated immunoglobulin production in Srsf2P95H/WT animals. Extensive mis-splicing of spliceosomal, epigenetic, and cytoskeletal regulators (Hnrnpa2b1, Rsrp1, H2az1, Erbin, Akap13) was also detected. scRNA-seq demonstrated a reduction in hematopoietic stem and progenitor cells (HSPCs) and an expansion of neutrophil precursors in Srsf2P95H/WT mice, verifying by flow-cytometry assay. A loss of Natural killer (NK) cells and effector T cells, together with a shift of the B-cell lineage from early precursor states toward more mature and transcriptionally active populations were detected in Srsf2P95H/WT group, accompanied by enrichment of antibody secretion-related programs. Sanger sequencing confirmed the presence of Srsf2 mutations in this B-cell subset and showed altered expression and alternative splicing of Hnrnpa2b1, a well-studied target of SRSF2 with P95 mutation. Collectively, these findings suggest that the Srsf2P95H/WT mutation contributes to the altered hematopoietic lineages composition and immune-related cellular states in BM, providing insights into its potential involvement in early-stage MDS and CMML progression.

PMID 43035463
阅读全文 →

注册免费账户还可查看另外 2314 篇文献

免费注册查看全部文献 →

了解更多TLX007-CDx